Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TS03 Inc Trust Units TSTIF

Healthcare Medical Instruments & Supplies


GREY:TSTIF - Post by User

TS03 Inc Trust Units > TSO3's PR Confusion and Canaccord Reiterates $5.25 Target..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Comment by Safetraderon Dec 06, 2016 7:24am
126 Views
Post# 25558636

RE:RE:RE:TSO3's PR Confusion and Canaccord Reiterates $5.25 Target..

RE:RE:RE:TSO3's PR Confusion and Canaccord Reiterates $5.25 Target..Agree the 18M is their full current backlog which includes :
  • Q4 monthly releases as per agreement
  • extra Q4 orders (over their minimum Getinge had to order,if any)
  • all 2017 orders for monthly releases
Normally increasing rate of production doesn't mean that plant is or will be in overcapacity.
Their annual releases must have a gradual yearly increase. Normal for a new product launch.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities